Loading
companiesCompany
Cancer Research Horizons
The innovation and commercial arm of the charity Cancer Research UK. It turns charity-funded discoveries into start-ups and licences, and runs a seed fund; its alumni include Autolus, KuDOS and Myricx Bio.
Overview
Cancer Research Horizons, based at 2 Redman Place, London E20, is the commercial and translational arm of Cancer Research UK. Its site covers a Therapeutic Accelerator, entrepreneurial training, a Seed Fund for investors, drug discovery groups (including a Functional Genomics Centre and Centre for Drug Development), licensing opportunities and multi-modal cancer datasets. Its start-up portfolio page states it has formed 95 or more start-ups across therapeutics, diagnostics and medtech, with 24 exits and more than GBP 3.55 billion raised by the portfolio. Exited companies listed include Autolus, KuDOS Pharmaceuticals (source of olaparib), Spirogen (antibody-drug conjugate payloads), Inivata (liquid biopsy), Monte Rosa Therapeutics and Myricx Bio (acquired by Novartis in a deal worth up to $1.5 billion); Trogenix, a glioblastoma immunotherapy company, is featured as an active start-up.
Portfolio (3)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Inivata Cambridge, GB | Acquired | diagnostics | Non-small-cell lung cancerHR-positive / HER2-negative breast cancerHead and neck squamous cell carcinoma | Acquisition 2021, $390M |
| Monte Rosa Therapeutics Boston, MA, US | Public | biotech | Prostate cancerOvarian cancer | none on record |
| Myricx Bio London, GB | Acquired | biotech | Acquisition 2026, $1.1B |
Notes
top- Launch year of the Cancer Research Horizons brand not stated on fetched pages; omitted. Autolus and Monte Rosa are already in the graph.